$2.660
-0.203 (-7.64%)收盤時
GNLX 資訊
GNLX 事件
Genelux Reports Significant Clinical Progress in Q2
"During the second quarter, the Company continued to make meaningful clinical and operational progress. We look forward to reporting the upcoming topline data of our Phase 3 OnPrime/GOG-3076 registrational trial, as well as dose-finding updates from our systemic administration studies in lung cancer," said Thomas Zindrick, President, CEO and Chairman of Genelux. "Recent translational findings further support Olvi-Vec's tumor-priming immunotherapy mechanism and its potential to promote tumor sensitization to platinum-based chemotherapy, as well as strengthening the scientific foundation of our ongoing clinical development programs."
Genelux Reports Significant Clinical Progress in Q2
"During the second quarter, the Company continued to make meaningful clinical and operational progress. We look forward to reporting the upcoming topline data of our Phase 3 OnPrime/GOG-3076 registrational trial, as well as dose-finding updates from our systemic administration studies in lung cancer," said Thomas Zindrick, President, CEO and Chairman of Genelux. "Recent translational findings further support Olvi-Vec's tumor-priming immunotherapy mechanism and its potential to promote tumor sensitization to platinum-based chemotherapy, as well as strengthening the scientific foundation of our ongoing clinical development programs."
Genelux Advances Olvi-Vec Clinical Trials
"As we build on our momentum entering 2026, we remain focused on disciplined execution of our registrational program. The randomized Phase 3 OnPrime/GOG-3076 trial remains on track for topline data in the second half of 2026. It is designed to generate robust, controlled clinical evidence intended to support filing for regulatory approval by demonstrating the efficacy of Olvi-Vec-primed immunochemotherapy relative to the active comparator arm," said Thomas Zindrick, President, CEO and Chairman of Genelux. "In addition, we continue to advance our systemic lung cancer programs as we evaluate Olvi-Vec's potential to resensitize tumors to platinum-based chemotherapy and expand beyond ovarian cancer."
Genelux Corporation Prices Public Offering of 6,666,667 Shares at $3.00 Each
Genelux Corporation announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share. All of the shares in the offering are to be sold by Genelux. The gross proceeds to Genelux from the offering are expected to be approximately $20M, before deducting underwriting discounts and commissions and estimated offering expenses payable by Genelux. In addition, Genelux has granted the underwriter a 30-day option to purchase up to an additional 1,000,000 shares of its common stock at the price to the public, less underwriting discounts and commissions. The net proceeds from the offering are expected to be used for general corporate purposes, which may include research and development expenses, clinical trial expenses, capital expenditures and working capital. The offering is expected to close on or about January 9, 2026, subject to the satisfaction of customary closing conditions. Lucid Capital Markets is acting as the sole book-running manager for the proposed offering.
Genelux Corporation Launches Proposed Public Offering
Genelux Corporation announced that it has commenced a proposed underwritten public offering of its common stock. All shares are being offered by Genelux. Lucid Capital Markets is acting as the sole book-running manager for the proposed offering.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。